智通财经APP讯,首药控股(688197.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶(MTAP)纯合缺失的局部晚期或转移性实体瘤的临床试验申请获得批准。
智通财经APP讯,首药控股(688197.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶(MTAP)纯合缺失的局部晚期或转移性实体瘤的临床试验申请获得批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.